SCHEMBL24196832

SCHEMBL24196832

C#Cc1c(C(=O)C2CC2)[nH]c2ccc(F)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2 P11137 1/20 0.41
MAPKAPK2 P49137 1/20 0.39
BRD3 Q15059 2/20 0.39
CFD P00746 1/20 0.38
KDM4E B2RXH2 3/20 0.38
MAPT P10636 2/20 0.38
PADI4 Q9UM07 1/20 0.38
FEN1 P39748 1/20 0.38
ALDH1A1 P00352 2/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
HTT P42858 1/20 0.36
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36
PDPK1 O15530 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
NFKB1 P19838 1/20 0.36
APEX1 P27695 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24196565 0.82 MAP2 (0.44) MAP2BRD3KDM4EMAPTFEN1
SCHEMBL24196937 0.81 GABRA1 (0.44) MAP2KDM4EMAPTFEN1ALDH1A1
SCHEMBL24196176 0.81 CNR1 (0.45) MAP2MAPKAPK2BRD3CFDKDM4E
SCHEMBL24196174 0.81 MAP2 (0.43) MAP2MAPKAPK2BRD3CFDKDM4E
SCHEMBL24196177 0.78 MAP2 (0.41) MAP2KDM4EMAPTFEN1ALDH1A1
SCHEMBL24196838 0.78 ALDH1A1 (0.49) MAP2MAPTFEN1ALDH1A1LMNA
SCHEMBL24196598 0.77 GABRA1 (0.52) MAP2KEAP1NFE2L2TSHRKMT2A
SCHEMBL24196828 0.75 GABRA1 (0.39) MAP2BRD3KDM4EFEN1KEAP1
SCHEMBL24197012 0.75 KMT2A (0.53) KDM4EMAPTALDH1A1GAAHTT
SCHEMBL26213340 0.75 TUBB4A (0.42) MAP2KDM4EMAPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115843271-B Indole derivatives and their use for the treatment of cancer 克洛德贝纳尔-里昂第一大学 2024-08-13 CN disclosed
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 US disclosed
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 US disclosed
CN-115843271-A Indole derivatives and their use for the treatment of cancer 克洛德贝纳尔-里昂第一大学 2023-03-24 CN disclosed
WO-2022008475-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2022-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER CSNK2A1, IDO1, CSNK2A3 MAP2 330/4885MAPKAPK2 354/4885BRD3 449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.